AbbVie Downplays Impact Of Viekira Pak Safety Issues
This article was originally published in Scrip
AbbVie Inc. continued to downplay the potential impact of a labeling change for its hepatitis C combination drug Viekira Pak, saying during its third quarter earnings call on Oct. 30 that the safety-driven update affects a small percentage of patients and won't prove material to the product's sales.
You may also be interested in...
A US FDA warning of serious liver injuries in hepatitis C patients treated with combo pills from AbbVie, Gilead and Merck may impact AbbVie's Mavyret most, since it's one of the company's top sellers.
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.